| Closed Momentum Options Trades for 2026: 23-4 (85%, 5 triple-digit winners); 2025: 55-20 (73%, 17 triple-digit winners); 2024: 77-17 (82%, 38 triple-digit winners); 2023: 34-11 (76%, 8 triple-digit winners). Overall: 189-52 (78% win rate) 68 triple-digit winners. Please remember, all “Exit Targets” and “Stop Targets” are targets. You should not have any “Stops” entered to close any alerts or “Limit Orders” in your brokerage account unless we list one. We will send out an “Alert” or “New Alert” if we want you to close a position or if a new position comes out. Otherwise, follow instructions at all times in the updates on Monday’s and Thursday’s along with Text Alerts and videos throughout the week. Text Alerts (Telegram):Velocity Options: https://t.me/+uzxYHX8YEh85MzYx Teucrium Corn Fund (CORN, $18.98, up $0.05) Option: CORN August 22 callsExpiration Date: August 21st, 2026Entry Option Price: $0.38 (5/13/2026)Current Option Price: $0.38Exit Target: $0.80Return: 0%Stop Target: None Action: Shares tested $19.13 on Wednesday and the peak from May 4th. Closes above this level could lead to a quick trip towards $19.50-$19.75. Rising support is at $18.75-$18.50. Closes above $19.75 gets the next wave of resistance at $20.75 in focus. This area represents a major resistance from February 2025. If cleared, CORN could run to the mid-$20’s.  KraneShares CSI China International ETF (KWEB, $30.59, up $1.44) Option: KWEB July 34 callsExpiration Date: July 17th, 2026Entry Option Price: $0.60 (5/11/2026)Current Option Price: $0.88Exit Target: $1.20Return: 47%Stop Target: 65 cents (Stop Limit) Action: Set an initial Stop Limit at 65 cents to start protecting profits and to avoid a loss. Shares zoomed 5% to break out of a nearly two-month trading range with the peak at $30.74. Lower resistance from early March at $30.50-$30.75 was recovered. Fresh support is at $30 and the top of the range. We have highlighted the $31.50 as the next speed bump ahead of an eventual run towards $33. Massive call volume has been hitting this stock since last Friday.  Plug Power (PLUG, $3.96, up $0.40) Option: PLUG September 4 callsExpiration Date: September 18th, 2026Entry Option Price: $0.50 (5/5/2026)Current Option Price: $0.92Exit Target: $1.00, raise to $2.00 (Limit Order on half)Return: 84%Stop Target: 60 cents Action: Set a Limit to close half the Alert at $2. Set a Stop Limit at 60 cents to start protecting profits and to avoid a loss. Shares zoomed to a high of $4.11 with key resistance at $4 getting topped but holding. Closes above this level get our near-term target of $4.50 in focus. Blue-sky territory up to $5-$6 could occur if $4.58 is cleared. We may send out additional Alerts this week if the parameters of the Alert change and adjustments are made. |
 |
Vale S.A. (VALE, $16.84, down $0.19) Option: VALE June 19 callsExpiration Date: June 18th, 2026Entry Option Price: $0.55 (4/20/2026)Current Option Price: $0.15Exit Target: $1.10Return: -73%Stop Target: None Action: Shares jumped 2.7% to start the week to clear and hold $17. Lower resistance at $16.75-$17 was cleared and held and held in Wednesday. Support is at $16.25-$16 and the 50-day moving average. |
 |
BioCryst Pharmaceuticals (BCRX, $9.60, up $0.80) Option: BCRX June 12 callsExpiration Date: June 18th, 2026Entry Option Price: $0.53 (3/24/2026)Current Option Price: $0.40Exit Target: $1.10Return: -25%Stop Target: None Action: Shares tagged a high of $9.79 with lower resistance at $9.75-$10 getting cleared but holding. New support is at $8.50-$8.75. Updated Highlights from earnings: * ORLADEYO sales were strong* The company kept its full-year revenue forecast* Management sounded confident about growth* Analysts raised price targets afterward ORLADEYO is important because its is a pill. Many competing drugs are injections/shots. Patients like pills more than needles so investors believe BioCryst has a strong advantage. Analysts repeatedly mentioned the “differentiated oral profile” as a reason doctorsand patients continue switching to ORLADEYO. The company signed a European licensing deal worth: $70 million upfront, potentially hundreds of millions more down the line. BioCryst acquired Astria Therapeutics and gained control of navenibart, a promising new drug. The deal was completed during the first quarter. Revenue beat estimates but the earnings numbers looked messy because of acquisition accounti |
 |